418 related articles for article (PubMed ID: 32000444)
1. Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review.
Pu D; Yin L; Zhou Y; Li W; Huang L; Cai L; Zhou Q
Medicine (Baltimore); 2020 Jan; 99(5):e19013. PubMed ID: 32000444
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection.
Shah NJ; Al-Shbool G; Blackburn M; Cook M; Belouali A; Liu SV; Madhavan S; He AR; Atkins MB; Gibney GT; Kim C
J Immunother Cancer; 2019 Dec; 7(1):353. PubMed ID: 31847881
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer: A Systematic Review.
Cook MR; Kim C
JAMA Oncol; 2019 Jul; 5(7):1049-1054. PubMed ID: 30730549
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series.
Kothapalli A; Khattak MA
Melanoma Res; 2018 Apr; 28(2):155-158. PubMed ID: 29406396
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection.
Pertejo-Fernandez A; Ricciuti B; Hammond SP; Marty FM; Recondo G; Rangachari D; Costa DB; Awad MM
Lung Cancer; 2020 Jul; 145():181-185. PubMed ID: 32423643
[TBL] [Abstract][Full Text] [Related]
6. Management of Hepatitis B Virus and Hepatitis C Virus Infections in Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Mustafayev K; Mallet V; Torres HA
J Immunother Precis Oncol; 2024 May; 7(2):111-121. PubMed ID: 38721408
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies.
Mustafayev K; Torres H
Clin Microbiol Infect; 2022 Oct; 28(10):1321-1327. PubMed ID: 35283317
[TBL] [Abstract][Full Text] [Related]
8. The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
Chai QQ; Du JY; Zhu J; Wu B
Front Pharmacol; 2019; 10():1260. PubMed ID: 31708783
[No Abstract] [Full Text] [Related]
9. Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C Virus Infection.
Alkrekshi A; Tamaskar I
Oncologist; 2021 May; 26(5):e827-e830. PubMed ID: 33655663
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.
Song P; Zhang D; Cui X; Zhang L
Thorac Cancer; 2020 Sep; 11(9):2406-2430. PubMed ID: 32643323
[TBL] [Abstract][Full Text] [Related]
11. Coinfection of Schistosoma Species with Hepatitis B or Hepatitis C Viruses.
Abruzzi A; Fried B; Alikhan SB
Adv Parasitol; 2016; 91():111-231. PubMed ID: 27015949
[TBL] [Abstract][Full Text] [Related]
12. Managing viral hepatitis in cancer patients under immune checkpoint inhibitors: should we take the risk?
De Keukeleire SJ; Vermassen T; Nezhad ZM; Kerre T; Kruse V; Vlierberghe HV; Vermaelen K; Rottey S
Immunotherapy; 2021 Apr; 13(5):409-418. PubMed ID: 33487052
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B Virus Reactivation in Cancer Patients Undergoing Immune Checkpoint Inhibitors Therapy: A Systematic Review.
Zhao J; Zhang Y; Qin S; Zou B; Wang Y
J Cancer; 2022; 13(14):3539-3553. PubMed ID: 36484006
[No Abstract] [Full Text] [Related]
14. Patient-Reported Outcomes for Cancer Patients Receiving Checkpoint Inhibitors: Opportunities for Palliative Care-A Systematic Review.
Hall ET; Singhal S; Dickerson J; Gabster B; Wong HN; Aslakson RA; Schapira L;
J Pain Symptom Manage; 2019 Jul; 58(1):137-156.e1. PubMed ID: 30905677
[TBL] [Abstract][Full Text] [Related]
15. A case-control study of hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Henan, China.
Zhang JY; Dai M; Wang X; Lu WQ; Li DS; Zhang MX; Wang KJ; Dai LP; Han SG; Zhou YF; Zhuang H
Int J Epidemiol; 1998 Aug; 27(4):574-8. PubMed ID: 9758109
[TBL] [Abstract][Full Text] [Related]
16. Active co-infection with HBV and/or HCV in South African HIV positive patients due for cancer therapy.
Musyoki AM; Msibi TL; Motswaledi MH; Selabe SG; Monokoane TS; Mphahlele MJ
J Med Virol; 2015 Feb; 87(2):213-21. PubMed ID: 25156907
[TBL] [Abstract][Full Text] [Related]
17. Management of autoimmune and viral hepatitis in immunotherapy: a narrative review.
Kuo L; Kuwelker S; Tsai E
Ann Palliat Med; 2023 Nov; 12(6):1275-1294. PubMed ID: 37731304
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitors in Patients With Cancer and Infection by Hepatitis B or C Virus: A Perspective Through the Results of a European Survey.
Tagliamento M; Remon J; Giaj Levra M; De Maria A; Bironzo P; Besse B; Novello S; Mezquita L
JTO Clin Res Rep; 2023 Jan; 4(1):100446. PubMed ID: 36687558
[TBL] [Abstract][Full Text] [Related]
19. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology.
Barbee MS; Ogunniyi A; Horvat TZ; Dang TO
Ann Pharmacother; 2015 Aug; 49(8):907-37. PubMed ID: 25991832
[TBL] [Abstract][Full Text] [Related]
20. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.
Conforti F; Pala L; Bagnardi V; De Pas T; Martinetti M; Viale G; Gelber RD; Goldhirsch A
Lancet Oncol; 2018 Jun; 19(6):737-746. PubMed ID: 29778737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
